15 results on '"Lazor, R."'
Search Results
2. Alveolar haemorrhage syndromes
- Author
-
Lazor, R., primary
- Published
- 2011
- Full Text
- View/download PDF
3. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
- Author
-
Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, A, Jayne, D, Guillevin, L, Cordier, J, Cordier, J., SINICO, RENATO ALBERTO, Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, A, Jayne, D, Guillevin, L, Cordier, J, Cordier, J., and SINICO, RENATO ALBERTO
- Abstract
The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail. In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease. The study population included 157 patients (mean±SD age 49.4±14.1 years), with a mean±SD blood eosinophil count of 7.4±6.4×109 L-1 at diagnosis. There was a mean±SD of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corticosteroid treatment, the severity of asthma increased 3-6 months before the onset of the systemic manifestations. Asthma was severe in 57%, 48%, and 56% of patients at diagnosis, at 3 years, and at the final visit, respectively. Persistent airflow obstruction was present in 38%, 30%, and 46% at diagnosis, at 3 years, and at the final visit, respectively. In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long-term management and morbidity.
- Published
- 2016
4. Primary ciliary dyskinesia
- Author
-
Lucas, J S A, Kuehni, C E, Lazor, R, and Walker, W T
- Subjects
otorhinolaryngologic diseases - Abstract
Primary ciliary dyskinesia (PCD) is an autosomal recessive disease with an incidence estimated between 1:2,000 and 1:40,000. Ciliated epithelia line the airways, nasal and sinus cavities, Eustachian tube and fallopian tubes. Congenital abnormalities of ciliary structure and function impair mucociliary clearance. As a consequence, patients present with chronic sinopulmonary infections, recurrent glue ear and female subfertility. Similarities in the ultrastructure of respiratory cilia, nodal cilia and sperm result in patients with PCD also presenting with male infertility, abnormalities of left-right asymmetry (most commonly situs inversus totalis) and congenital heart disease. Early diagnosis is essential to ensure specialist management of the respiratory and otological complications of PCD. Diagnostic tests focus on analysis of ciliary function and electron microscopy structure. Analysis is technically difficult and labour intensive. It requires expertise for interpretation, restricting diagnosis to specialist centres. Management is currently based on the consensus of experts, and there is a pressing need for randomised clinical trials to inform treatment.
- Published
- 2011
- Full Text
- View/download PDF
5. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
- Author
-
Johnson, S R, Cordier, J F, Lazor, R, Cottin, V, Costabel, U, Harari, S, Reynaud-Gaubert, M, Boehler, A, Brauner, M, Popper, H, Bonetti, F, and Kingswood, C
- Subjects
3. Good health
6. Respiratory symptoms of Swiss people with primary ciliary dyskinesia.
- Author
-
Goutaki M, Hüsler L, Lam YT, Koppe HM, Jung A, Lazor R, Müller L, Pedersen ESL, and Kuehni CE
- Abstract
Background: Mostly derived from chart reviews, where symptoms are recorded in a nonstandardised manner, clinical data about primary ciliary dyskinesia (PCD) are inconsistent, which leads to missing and unreliable information. We assessed the prevalence and frequency of respiratory and ear symptoms and studied differences by age and sex among an unselected population of Swiss people with PCD., Methods: We sent a questionnaire that included items from the FOLLOW-PCD standardised questionnaire to all Swiss PCD registry participants., Results: We received questionnaires from 74 (86%) out of 86 invited persons or their caregivers (median age 23 years, range 3-73 years), including 68% adults (≥18 years) and 51% females. Among participants, 70 (94%) reported chronic nasal symptoms; most frequently runny nose (65%), blocked nose (55%) or anosmia (38%). Ear pain and hearing problems were reported by 58% of the participants. Almost all (99%) reported cough and sputum production. The most common chronic cough complications were gastro-oesophageal reflux (n=11; 15%), vomiting (n=8; 11%) and urinary incontinence (n=6; 8%). Only nine (12%) participants reported frequent wheeze, which occurred mainly during infection or exercise, while 49 (66%) reported shortness of breath, and 9% even at rest or during daily activities. Older patients reported more frequent nasal symptoms and shortness of breath. We found no difference by sex or ultrastructural ciliary defect., Conclusion: This is the first study to describe patient-reported PCD symptoms. The consistent collection of standardised clinical data will allow us to better characterise the phenotypic variability of the disease and study disease course and prognosis., Competing Interests: Conflict of interest: M. Goutaki reports support for the present manuscript received from the Swiss National Science Foundation, and is co-chair of the BEAT-PCD ERS clinical research collaboration and chair of the ERS paediatric epidemiology group, outside the submitted work. The remaining authors have nothing to disclose., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
7. Birt-Hogg-Dubé syndrome.
- Author
-
Daccord C, Good JM, Morren MA, Bonny O, Hohl D, and Lazor R
- Subjects
- Humans, Tomography, X-Ray Computed, Birt-Hogg-Dube Syndrome diagnostic imaging, Birt-Hogg-Dube Syndrome genetics, Cysts, Lung Diseases diagnostic imaging, Lung Diseases genetics, Pneumothorax etiology, Pneumothorax genetics
- Abstract
Birt-Hogg-Dubé syndrome (BHD) is a rare inherited autosomal dominant disorder caused by germline mutations in the tumour suppressor gene FLCN , encoding the protein folliculin. Its clinical expression typically includes multiple pulmonary cysts, recurrent spontaneous pneumothoraces, cutaneous fibrofolliculomas and renal tumours of various histological types. BHD has no sex predilection and tends to manifest in the third or fourth decade of life. Multiple bilateral pulmonary cysts are found on chest computed tomography in >80% of patients and more than half experience one or more episodes of pneumothorax. A family history of pneumothorax is an important clue, which suggests the diagnosis of BHD. Unlike other cystic lung diseases such as lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis, BHD does not lead to progressive loss of lung function and chronic respiratory insufficiency. Renal tumours affect about 30% of patients during their lifetime, and can be multiple and recurrent. The diagnosis of BHD is based on a combination of genetic, clinical and/or skin histopathological criteria. Management mainly consists of early pleurodesis in the case of pneumothorax, periodic renal imaging for tumour detection, and diagnostic work-up in search of BHD in relatives of the index patient., Competing Interests: Provenance: Commissioned article, peer reviewed. Conflict of interest: C. Daccord reports non-financial support from Boehringer-Ingelheim and Roche, outside the submitted work. Conflict of interest: J-M. Good has nothing to disclose. Conflict of interest: M-A. Morren has nothing to disclose. Conflict of interest: O. Bonny has nothing to disclose. Conflict of interest: D. Hohl has nothing to disclose. Conflict of interest: R. Lazor reports personal fees and non-financial support from Boehringer-Ingelheim, and non-financial support from Roche and Vifor, outside the submitted work., (Copyright ©ERS 2020.)
- Published
- 2020
- Full Text
- View/download PDF
8. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study.
- Author
-
Pozzessere C, Bouchaab H, Jumeau R, Letovanec I, Daccord C, Bourhis J, Prior JO, Peters S, Lazor R, and Beigelman-Aubry C
- Abstract
In patients with primary or secondary lung tumour treated with immune checkpoint inhibitors, immune-related pneumonitis is a rare adverse event but may evolve to respiratory failure. Prompt management is required and usually consists of treatment interruption and immunosuppressive drug administration. The aim of this study was to evaluate relationships between immune-related pneumonitis and pre-existing parenchymal status, especially tumour location and history of chest radiotherapy. Computed tomography (CT) scans of patients with immune-related pneumonitis were retrospectively reviewed. Pattern, distribution and extent of pneumonitis were assessed in six lung regions. In patients who received radiotherapy, the extent of pneumonitis was evaluated according to the radiation field. Among 253 patients treated with immunotherapy, 15 cases of immune-related pneumonitis were identified. 10 had previous or concomitant chest radiotherapy in addition to immunotherapy. At CT scan, 29 (33%) out of 88 regions encompassed the primary tumour (n=4), a lung metastasis (n=4) and/or radiation fields (n=21). A significantly higher prevalence of parenchymal involvement by immune-related pneumonitis occurred within areas of primary or metastatic malignancy and/or radiation field (97%) as compared to other areas (3%, p=0.009). Lung regions affected by the primary tumour, metastasis or radiotherapy had a higher probability of immune-related pneumonitis than others (OR 10.8, p=0.024). An organising pneumonia (OP) pattern was more frequent after radiotherapy (70% versus 0%, p=0.024), whereas nonspecific interstitial pneumonia features were more commonly seen in radiotherapy-naive patients (100% versus 10%, p=0.002). In patients with primary or secondary lung tumour treated with immune checkpoint inhibitors, immune-related pneumonitis is preferentially located within lung areas involved by tumour and/or radiation fields., Competing Interests: Conflict of interest: C. Pozzessere has nothing to disclose. Conflict of interest: H. Bouchaab has nothing to disclose. Conflict of interest: R. Jumeau has nothing to disclose. Conflict of interest: I. Letovanec has nothing to disclose. Conflict of interest: C. Daccord has nothing to disclose. Conflict of interest: J. Bourhis has nothing to interest. Conflict of interest: J.O. Prior has nothing to disclose. Conflict of interest: S. Peters reports personal fees for advisory boards and honoraria from Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics and Takeda; personal fees for talks and honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Merck Sharp and Dohme, Novartis, Pfizer and Takeda; non-financial support for investigation in trials sponsored by Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis and Pfizer; non-financial support for a talk and an honorarium from Sanofi, all outside the submitted work. Conflict of interest: R. Lazor reports personal fees for travel costs for continuing education from Boehringer Ingelheim, Roche and Vifor, outside the submitted work. Conflict of interest: C. Beigelman-Aubry reports personal fees for lectures from Gilead, AstraZeneca and Boehringer, outside the submitted work., (Copyright ©ERS 2020.)
- Published
- 2020
- Full Text
- View/download PDF
9. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
- Author
-
Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, Sinico RA, Sivasothy P, Wechsler ME, Groh M, Marchand-Adam S, Khouatra C, Wallaert B, Taillé C, Delaval P, Cadranel J, Bonniaud P, Prévot G, Hirschi S, Gondouin A, Dunogué B, Chatté G, Briault A, Jayne D, Guillevin L, and Cordier JF
- Subjects
- Administration, Oral, Adolescent, Adrenal Cortex Hormones administration & dosage, Adult, Aged, Aged, 80 and over, Asthma physiopathology, Bronchoalveolar Lavage, Churg-Strauss Syndrome complications, Eosinophilia physiopathology, Female, France, Granulomatosis with Polyangiitis complications, Humans, Male, Middle Aged, Prognosis, Respiratory Function Tests, Retrospective Studies, Severity of Illness Index, Systemic Vasculitis physiopathology, Tomography, X-Ray Computed, Treatment Outcome, Young Adult, Churg-Strauss Syndrome physiopathology, Eosinophils cytology, Granulomatosis with Polyangiitis physiopathology
- Abstract
The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail.In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease.The study population included 157 patients (mean±sd age 49.4±14.1 years), with a mean±sd blood eosinophil count of 7.4±6.4×10
9 L-1 at diagnosis. There was a mean±sd of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corticosteroid treatment, the severity of asthma increased 3-6 months before the onset of the systemic manifestations. Asthma was severe in 57%, 48%, and 56% of patients at diagnosis, at 3 years, and at the final visit, respectively. Persistent airflow obstruction was present in 38%, 30%, and 46% at diagnosis, at 3 years, and at the final visit, respectively.In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long-term management and morbidity., (Copyright ©ERS 2016.)- Published
- 2016
- Full Text
- View/download PDF
10. Monoallelic germline ATM mutation and organising pneumonia induced by radiation therapy to the breast.
- Author
-
Cordier JF, Cottin V, Lazor R, and Stoppa-Lyonnet D
- Subjects
- Adult, Aged, Anti-Inflammatory Agents administration & dosage, Ataxia Telangiectasia genetics, Breast Neoplasms surgery, Fatal Outcome, Female, Germ-Line Mutation, Humans, Male, Prednisone administration & dosage, Tomography, X-Ray Computed, Young Adult, Ataxia Telangiectasia Mutated Proteins genetics, Breast Neoplasms radiotherapy, Radiation Pneumonitis diagnostic imaging, Radiation Pneumonitis drug therapy
- Published
- 2016
- Full Text
- View/download PDF
11. Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis.
- Author
-
Bouvry D, Mouthon L, Brillet PY, Kambouchner M, Ducroix JP, Cottin V, Haroche J, Viallard JF, Lazor R, Lebargy F, Tazi A, Wallaert B, Smail A, Pellegrin JL, Nunes H, Amoura Z, Cordier JF, Valeyre D, and Naccache JM
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Child, Common Variable Immunodeficiency complications, Female, Granuloma complications, Humans, Lung Diseases, Interstitial complications, Male, Middle Aged, Retrospective Studies, Young Adult, Common Variable Immunodeficiency diagnosis, Granuloma diagnosis, Lung Diseases, Interstitial diagnosis, Sarcoidosis, Pulmonary diagnosis
- Abstract
The aim of the present study was to investigate to what extent interstitial lung disease (ILD) in common variable immunodeficiency disorder (CVID)-associated granulomatous disease (GD) is similar to pulmonary sarcoidosis 20 patients with CVID/GD were included in a retrospective study conducted by the Groupe Sarcoïdose Francophone. Medical records were centralised. Patients were compared with 60 controls with sarcoidosis. Clinical examination showed more frequent crackles in patients than controls (45% versus 1.7%, respectively; p<0.001). On thoracic computed tomography scans, nodules (often multiple and with smooth margins), air bronchograms and halo signs were more frequent in patients than controls (80% versus 42%, respectively; p=0.004) as well as bronchiectasis (65% versus 23%, respectively; p<0.001). The micronodule distribution was perilymphatic in 100% of controls and in 42% of patients (p<0.001). Bronchoalveolar lavage analysis showed lower T-cell CD4/CD8 ratios in patients than in controls (mean ± sd 1.6 ± 1.1 versus 5.3 ± 4, respectively; p<0.01). On pathological analysis, nodules and consolidations corresponded to granulomatous lesions with or without lymphocytic disorders in most cases. Mortality was higher in patients than controls (30% versus 0%, respectively) and resulted from common variable immunodeficiency complications. ILD in CVID/GD presents a specific clinical picture and evolution that are markedly different from those of sarcoidosis.
- Published
- 2013
- Full Text
- View/download PDF
12. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.
- Author
-
Cottin V, Harari S, Humbert M, Mal H, Dorfmüller P, Jaïs X, Reynaud-Gaubert M, Prevot G, Lazor R, Taillé C, Lacronique J, Zeghmar S, Simonneau G, and Cordier JF
- Subjects
- Adult, Breath Tests, Carbon Monoxide analysis, Cardiac Catheterization, Exercise Test, Female, Hemodynamics, Humans, Hypertension, Pulmonary mortality, Hypertension, Pulmonary therapy, Lymphangioleiomyomatosis mortality, Lymphangioleiomyomatosis therapy, Middle Aged, Oxygen blood, Oxygen therapeutic use, Respiratory Function Tests, Retrospective Studies, Vascular Resistance physiology, Hypertension, Pulmonary physiopathology, Lymphangioleiomyomatosis physiopathology
- Abstract
This retrospective, multicentre study evaluated patients with lymphangioleiomyomatosis (LAM) and pre-capillary pulmonary hypertension (PH) by right heart catheterisation. It was conducted in 20 females with a mean ± SD age of 49 ± 12 yrs and a mean ± SD time interval between LAM and PH diagnoses of 9.2 ± 9.8 yrs. All, except for one patient, were receiving supplemental oxygen. 6-min walking distance was mean ± SD 340 ± 84 m. Haemodynamic characteristics were: mean pulmonary artery pressure (PAP) 32 ± 6 mmHg, cardiac index 3.5 ± 1.1 L · min(-1) · m(-2) and pulmonary vascular resistance (PVR) 376 ± 184 dyn · s · cm(-5). Mean PAP was >35 mmHg in only 20% of cases. The forced expiratory volume in 1 s was 42 ± 25%, carbon monoxide transfer factor was 29 ± 13%, and arterial oxygen tension (P(a,O(2))) was 7.4 ± 1.3 kPa in room air. Mean PAP and PVR did not correlate with P(a,O(2)). In six patients who received oral pulmonary arterial hypertension (PAH) therapy, the PAP decreased from 33 ± 9 mmHg to 24 ± 10 mmHg and the PVR decreased from 481 ± 188 dyn · s · cm(-5) to 280 ± 79 dyn · s · cm(-5). The overall probability of survival was 94% at 2 yrs. Pre-capillary PH of mild haemodynamic severity may occur in patients with LAM, even with mild pulmonary function impairment. PAH therapy might improve the haemodynamics in PH associated with LAM.
- Published
- 2012
- Full Text
- View/download PDF
13. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.
- Author
-
Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H, Bonetti F, and Kingswood C
- Subjects
- Humans, Lung Transplantation, Lymphangioleiomyomatosis complications, Lymphangioleiomyomatosis diagnosis, Lymphangioleiomyomatosis therapy
- Published
- 2010
- Full Text
- View/download PDF
14. Pulmonary hypertension therapy and COPD: still many questions to be answered.
- Author
-
Cottin V, Khouatra C, Lazor R, Canu P, and Cordier JF
- Subjects
- Antihypertensive Agents pharmacology, Bosentan, Humans, Lung drug effects, Pulmonary Artery pathology, Pulmonary Disease, Chronic Obstructive pathology, Research Design, Sulfonamides pharmacology, Treatment Outcome, Hypertension, Pulmonary complications, Hypertension, Pulmonary drug therapy, Pulmonary Disease, Chronic Obstructive complications
- Published
- 2009
- Full Text
- View/download PDF
15. Should patients with lymphangioleiomyomatosis undergo screening for meningioma?
- Author
-
Cottin V, Vukusic S, Jouanneau E, Lazor R, and Cordier JF
- Subjects
- Adult, Female, Humans, Meningeal Neoplasms complications, Meningioma complications, Lung Neoplasms complications, Lymphangioleiomyomatosis complications, Meningeal Neoplasms diagnosis, Meningioma diagnosis
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.